Lacerta Therapeutics Expands Executive Leadership Team

UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: Kenneth Warrington, Jr., PhD, co-founder of Lacerta, has joined as the company’s Chief Technology Officer (CTO), and Darin Falk, PhD, former Vice President of Gene Therapy Programs at Lacerta, will now serve as the company’s Chief Scientific Officer (CSO). Both Warrington and Falk represent significant additions to CEO Edgar Rodriguez-Lebron’s executive team, and further illustrate Lacerta’s commitment to developing a constellation of gene-based therapies.

Lacerta Therapeutics is a UF Innovate | Accelerate at Sid Martin Biotech graduate.

Learn more about Lacerta Therapeutics Expands Executive Leadership Team